NCT05641142 Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia
| NCT ID | NCT05641142 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Clermont-Ferrand |
| Condition | Hereditary Hemorrhagic Telangiectasia |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-04-07 |
| Primary Completion | 2029-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2023-04-07 with a primary completion date of 2029-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate in real life, in patients with Hereditary Hemorrhagic Telangiectasia (HHT), the tolerance of the strategy of use of anticoagulant and/or antiplatelet, by comparing a new exposure period (first trimester of treatment) to a period of reference non-exposure (last trimester before start of treatment).
Eligibility Criteria
Inclusion Criteria: * Patient with Rendu-Osler disease with an indication of antiplatelet and/or anticoagulant introduced for less than 3 months (inclusion period within 3 months of exposure) * Age \> 18 years old * Patient able to understand and agree to participate in the study * Affiliation to a social security system Exclusion Criteria: * Patient with an indication of antiplatelet and/or anticoagulant but for whom treatment has not been introduced or introduced for more than 3 months * Refusal to participate * Pregnant woman or who are breast feeding * Patients under maintenance of justice, wardship or legal guardianship
Contact & Investigator
Vincent GROBOST
PRINCIPAL INVESTIGATOR
University Hospital, Clermont-Ferrand
Frequently Asked Questions
Who can join the NCT05641142 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hereditary Hemorrhagic Telangiectasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05641142 currently recruiting?
Yes, NCT05641142 is actively recruiting participants. Contact the research team at promo_interne_drci@chu-clermontferrand.fr for enrollment information.
Where is the NCT05641142 trial being conducted?
This trial is being conducted at Angers, France, Bordeaux, France, Boulogne-Billancourt, France, Caen, France and 11 additional locations.
Who is sponsoring the NCT05641142 clinical trial?
NCT05641142 is sponsored by University Hospital, Clermont-Ferrand. The principal investigator is Vincent GROBOST at University Hospital, Clermont-Ferrand. The trial plans to enroll 100 participants.